A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples